510(k) Premarket Notification: The Complete Guide

What Is a 510(k) Premarket Notification?

A 510(k) is a premarket submission made to FDA to demonstrate that a device to be marketed is at least as safe and effective as a legally marketed device that is not subject to premarket approval. The legally marketed device is known as the predicate device. Submitters must compare their device to one or more predicate devices and demonstrate substantial equivalence (SE).

The 510(k) program takes its name from Section 510(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). It is the most common pathway for medical devices to reach the US market. FDA receives approximately 3,000 to 4,000 traditional 510(k) submissions annually, clearing roughly 80-85% of them.

A 510(k) clearance is distinct from PMA approval. While PMA requires clinical evidence proving safety and effectiveness (typically for Class III high-risk devices), a 510(k) requires demonstrating that a new device is substantially equivalent to an existing legally marketed device. This approach allows innovative devices to reach patients more quickly while still ensuring appropriate safety standards. For a deeper look at the PMA pathway, see our PMA Premarket Approval guide.

When Is a 510(k) Required?

A 510(k) premarket notification is required before marketing a medical device in the United States in the following situations:

• New device introduction: Introducing a device to the US market for the first time, unless the device is exempt from 510(k) requirements
• Significant device modification: Making a change to a previously cleared device that could significantly affect safety or effectiveness, including changes to intended use, design, materials, energy source, or manufacturing process
• New intended use: Changing the intended use or indications for use of a cleared device, even if the physical device remains unchanged
• Reintroduction after suspension: Reintroducing a device after its clearance has been rescinded or suspended

When a 510(k) Is NOT Required

• Class I devices that are 510(k)-exempt (the majority of Class I devices)
• Class II devices that FDA has specifically exempted from 510(k) requirements
• Devices marketed before the Medical Device Amendments of 1976 (preamendment devices) that have not been significantly modified
• Custom devices meeting all criteria under Section 520(b) of the FD&C Act
• Devices intended solely for investigational use under an Investigational Device Exemption (IDE) — see our IDE guide

Types of 510(k) Submissions

FDA accepts three types of 510(k) submissions, each designed for different scenarios. Selecting the right type can significantly affect review time and documentation burden.

The Traditional 510(k) is the most commonly submitted type and provides the greatest flexibility. A Special 510(k) is available only for modifications to your own cleared device where the change is evaluated through design control procedures. An Abbreviated 510(k) relies on FDA-recognized consensus standards, guidance documents, or special controls to streamline the SE demonstration.

Finding a Predicate Device

Selecting the right predicate device is arguably the most critical strategic decision in the entire 510(k) process. A strong predicate shares both the intended use and technological characteristics of your device, making the SE argument straightforward. A weak predicate selection is one of the top reasons for FDA Additional Information requests and NSE determinations.

Where to Search for Predicates

• FDA 510(k) Premarket Notification Database — Search all cleared 510(k) submissions by applicant name, device name, product code, clearance date, or decision summary
• FDA Product Classification Database — Identify the correct product code and regulation number for your device type, which helps narrow predicate searches
• Assurentry Predicate Finder Tool — Our AI-powered tool helps identify potential predicate devices based on your device description, intended use, and product code
• Summary Decision Letters: Review Summary of Safety and Effectiveness Data (SSED) documents for cleared devices in your product category to understand FDA's expectations

Predicate Selection Strategy

When evaluating potential predicate devices, prioritize the following criteria:

• Same intended use: The predicate must share the same intended use as your device. This is the threshold requirement — without it, SE cannot be established.
• Same technological characteristics: Devices with the same materials, design, energy source, and mechanism of action result in the simplest SE arguments.
• Recent clearance: More recently cleared predicates reflect current FDA expectations and testing standards.
• Detailed decision summary: Predicates with published Summaries of Safety and Effectiveness provide insight into what testing and data FDA required.

Substantial Equivalence Determination

Substantial equivalence (SE) is the regulatory standard that a 510(k) must satisfy. FDA determines SE through a two-part analysis:

Step 1: Intended Use Comparison

The new device must have the same intended use as the predicate device. Intended use includes the general purpose of the device (e.g., measuring blood glucose levels) and may include specific indications for use (e.g., for use by patients with diabetes in home settings). If the intended use differs, FDA will issue an NSE determination regardless of technological similarity.

Step 2: Technological Characteristics Comparison

If the intended use is the same, FDA compares technological characteristics:

• Same technological characteristics: If the device has the same materials, design, energy source, and other features as the predicate, FDA makes an SE determination. No performance data may be needed.
• Different technological characteristics: If differences exist, the submitter must demonstrate that the differences do not raise new questions of safety and effectiveness, and that the device is at least as safe and effective as the predicate. This typically requires performance testing data (bench testing, biocompatibility testing, and potentially clinical data).

Preparing Your 510(k) Submission Package

A complete 510(k) submission, now required to use the eSTAR electronic format, includes multiple sections. The following checklist covers the essential components required for a traditional 510(k):

For software-containing devices, FDA also expects cybersecurity documentation aligned with the 2023 guidance on Cybersecurity in Medical Devices. See the full Medical Device 510(k) Guide for additional detail on testing requirements and QMSR compliance.

FDA Review Process and Timeline

The FDA 510(k) review process follows a structured sequence from submission through final determination. Understanding each phase helps set realistic timeline expectations.

Phase 1: Administrative Review (RTA)

Within 15 business days of receipt, FDA conducts a Refuse to Accept (RTA) screening. Submissions that fail the RTA checklist are returned without substantive review. Using the eSTAR template significantly reduces RTA rates. The RTA review checks for completeness, proper formatting, required forms, user fee payment, and all mandatory content sections.

Phase 2: Substantive Review

Once accepted, an FDA reviewer conducts a detailed evaluation of the SE argument, performance data, labeling, and device description. The MDUFA V performance goal is to complete substantive review within 90 FDA days for traditional 510(k) submissions.

Phase 3: Additional Information (AI) Requests

If FDA needs clarification or additional data, an AI letter is issued. The review clock pauses until the submitter responds. Common AI topics include:

• Clarification of device description or intended use
• Additional bench or biocompatibility test results
• More detailed predicate comparison or justification
• Labeling modifications or additional warnings
• Software documentation gaps or cybersecurity questions

Phase 4: Decision

FDA issues one of three determinations:

• Substantially Equivalent (SE): The device is cleared for commercial distribution in the United States
• Not Substantially Equivalent (NSE): The device cannot be marketed via the 510(k) pathway. Consider De Novo or PMA alternatives.
• Withdrawn: The submitter voluntarily withdraws the submission, typically to address deficiencies and resubmit

Common 510(k) Deficiencies and Rejections

Understanding the most frequent reasons FDA issues AI requests or NSE determinations helps you build a stronger submission. The following deficiency categories represent the most common issues identified during FDA review:

510(k) Fees and Costs (FY2026)

The FDA user fee for 510(k) submissions is established annually under the Medical Device User Fee Amendments (MDUFA). FY2026 fees (effective October 1, 2025 through September 30, 2026) are as follows:

Total Cost Considerations

Beyond the FDA user fee, total 510(k) project costs include:

• Performance testing: $10,000 - $100,000+ depending on device type and required standards (biocompatibility, electrical safety, EMC, sterility validation)
• Regulatory consulting: $15,000 - $50,000 for submission preparation and strategy
• Clinical data (if needed): $50,000 - $500,000+ for clinical studies; not always required for 510(k)
• Quality system development: ISO 13485/QMSR compliance costs vary significantly by company size and existing quality infrastructure

For small businesses, FDA offers a 75% fee reduction on 510(k) submission fees. To qualify, a company must have gross receipts or sales of $100 million or less (including affiliates) and submit a small business qualification request to CDRH prior to or concurrent with the 510(k) submission.

How Assurentry Supports 510(k) Submissions

Assurentry provides end-to-end support for medical device companies navigating the 510(k) pathway. Our platform and compliance team help at every stage of the process:

For a broader overview of FDA medical device requirements beyond the 510(k) process, see our Medical Device Registration & Listing Guide and the comprehensive 510(k) Submission Guide which covers QMSR compliance, post-clearance obligations, and adverse event reporting in detail.

Frequently Asked Questions